Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 10/20 | 0.54 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.54 |
| ▸ | ALK | Q9UM73 | 8/20 | 0.53 |
| ▸ | INSR | P06213 | 2/20 | 0.52 |
| ▸ | IGF1R | P08069 | 2/20 | 0.52 |
| ▸ | JAK3 | P52333 | 1/20 | 0.52 |
| ▸ | JAK2 | O60674 | 1/20 | 0.52 |
| ▸ | SRC | P12931 | 1/20 | 0.52 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30621968 | 0.88 | EGFR (0.59) | EGFRMAP3K7ALKINSRIGF1R | |
| SCHEMBL29097707 | 0.88 | EGFR (0.59) | EGFRMAP3K7ALKINSRIGF1R | |
| SCHEMBL29097715 | 0.87 | SLC2A1 (0.51) | EGFRMAP3K7ALKSRC | |
| SCHEMBL31318199 | 0.84 | ALK (0.54) | EGFRMAP3K7ALKJAK3 | |
| SCHEMBL29097720 | 0.83 | EGFR (0.51) | EGFRMAP3K7ALKINSRIGF1R | |
| SCHEMBL29097557 | 0.82 | EGFR (0.54) | EGFRALKINSRIGF1RJAK2 | |
| SCHEMBL18491223 | 0.76 | EGFR (0.73) | EGFRMAP3K7ALKINSRIGF1R | |
| SCHEMBL886288 | 0.74 | ALK (0.73) | EGFRMAP3K7ALKINSRIGF1R | |
| SCHEMBL27057252 | 0.73 | PLK1 (0.68) | EGFRMAP3K7ALKINSRIGF1R | |
| SCHEMBL16371969 | 0.73 | ALK (0.77) | EGFRMAP3K7ALKINSRIGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116903592-A | Pyrimidine amine NUAK inhibitor and preparation method and application thereof | 特科罗生物科技(成都)有限公司 | 2023-10-20 | — | — | CN | disclosed |